Marek Brzosko - Concepedia

Author

Marek Brzosko

Also Known As

Brzosko, Marek, Daniel Brito de Araujo, M BRZOSKO, M Brzosko, M. Brzosko, MAREK BRZOSKO, Maciej Brzosko, Marek Brzosko, Marek Brzosko Brzosko, Piercarlo Sarzi Puttini

254

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Pomeranian Medical University Medical University of Lublin Wroclaw Medical University National Institute of Geriatrics, Rheumatology and Rehabilitation Gdańsk Medical University

About

Marek Brzosko is an author at Pomeranian Medical University specializing in medicine, rheumatology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	240
2	Immunology	4	4	124
3	Public Health	1	1	35
4	Emergency Medicine	1	1	35
5	Epidemiology	1	1	43

Marek Brzosko

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu Joel M. Kremer, Ricardo Blanco, Marek Brzosko, Arthritis & Rheumatism	2010	410
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study Won Park, Dae‐Hyun Yoo, Pedro C. Miranda, Annals of the Rheumatic Diseases	2016	227
The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis Andrzej Pawlik, Lidia Ostanek, Iwona Brzosko, Arthritis Research & Therapy	2003	123
Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results Roy Fleischmann, Anne-Marie Halland, Marek Brzosko, The Journal of Rheumatology	2013	121
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib R. Lehmann, Marek Brzosko, Petr Kopsa, Current Medical Research and Opinion	2005	73
Serum IL‐6 and IL‐23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome Hanna Przepiera‐Będzak, Katarzyna Fischer, Marek Brzosko Mediators of Inflammation	2015	59
Factors associated with quality of life in systemic sclerosis: a cross-sectional study Matylda Sierakowska, Halina Doroszkiewicz, Justyna Sierakowska, Quality of Life Research	2019	51
Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome Hanna Przepiera‐Będzak, Katarzyna Fischer, Marek Brzosko International Journal of Molecular Sciences InflammationRheumatologySerum Il-18Rheumatoid DisorderAutoimmune Disease	2016	48
Is prevalence of PBC underestimated in patients with systemic sclerosis? Gary L. Norman, Susan Encabo, B. Butkiewicz, Digestive and Liver Disease EpidemiologyClinical FindingAutoimmune DiseaseDisease ProgressionSystemic Sclerosis	2009	43
Cardiac Arrhythmias and Conduction Disturbances in Patients With Ankylosing Spondylitis Jarosław Kaźmierczak, Małgorzata Peregud‐Pogorzelska, Jowita Biernawska, Angiology Heart FailureVentricular ExtrasystolesConduction DisturbancesAxial SpondyloarthritisElectrophysiological Evaluation	2007	35

Page 1